MSLE
Satellos Bioscience Inc. Common Stock
NASDAQ · Healthcare · Medical - Pharmaceuticals · CA
$8.97
−1.21%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 4.0K | 5.1K | 20.0K | 5.3K | 3.7M |
| Gross Profit | (4.0K) | (5.1K) | (20.0K) | (5.3K) | (3.7M) |
| Operating Expenses | |||||
| R&D Expense | 26.1M | 18.4M | 13.7M | 6.6M | 3.7M |
| SG&A Expense | 8.8M | 7.4M | 5.2M | 4.6M | 4.7M |
| General & Admin Expense | 8.8M | 7.4M | 5.2M | 4.6M | 4.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 589.7K | 595.0K | 554.6K | 442.5K | (3.7M) |
| Total Operating Expenses | 35.5M | 26.5M | 19.4M | 11.7M | 4.7M |
| Cost and Expenses | 35.5M | 26.5M | 19.4M | 11.7M | 8.4M |
| Operating Income (EBIT) | (35.5M) | (26.5M) | (19.4M) | (11.7M) | (8.4M) |
| Non-Operating | |||||
| Interest Income | 1.6M | 1.4M | 955.3K | 1.0M | 63.0K |
| Interest Expense | — | — | — | 133.4K | — |
| Net Interest Income | 1.6M | 1.4M | 955.3K | 871.4K | 63.0K |
| Other Non-Op Income/Expense | 1.4M | 1.8M | (202.8K) | (321.1K) | (2.9M) |
| Non-Operating Income (excl Interest) | — | — | 202.8K | 187.7K | — |
| EBT (Pre-Tax Income) | (34.2M) | (24.7M) | (19.6M) | (12.0M) | (11.3M) |
| Income Tax Expense | 152.9K | 172.0K | — | — | 5.0K |
| Bottom Line | |||||
| Net Income | (34.3M) | (24.9M) | (19.6M) | (12.0M) | (11.3M) |
| Earnings from Cont. Ops | (34.3M) | (24.9M) | (19.6M) | (12.0M) | (11.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (34.3M) | (24.9M) | (28.1M) | (12.0M) | (11.3M) |
| Per Share | |||||
| Basic EPS | ($1.92) | ($20.40) | ($2.16) | ($1.63) | ($3.81) |
| Diluted EPS | ($1.92) | ($20.40) | ($2.16) | ($1.63) | ($3.81) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 20.8M | 1.2M | 9.6M | 7.2M | 3.0M |
| Diluted Shares Outstanding | 20.8M | 1.2M | 9.6M | 7.2M | 3.0M |
| Profitability Metrics | |||||
| EBITDA | (35.5M) | (26.5M) | (19.6M) | (11.8M) | (8.1M) |
| D&A | 6.0K | 5.0K | 13.9K | 5.3K | 337.0K |
| EBIT | (35.5M) | (26.5M) | (19.6M) | (11.8M) | (8.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026